Chemical modification of bradykinin-polymer conjugates for optimum delivery of nanomedicines to tumors
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články
PubMed
38460653
DOI
10.1016/j.nano.2024.102744
PII: S1549-9634(24)00013-3
Knihovny.cz E-zdroje
- Klíčová slova
- Bradykinin, Controlled release, HPMA polymer, Hydrazone, Tumor,
- MeSH
- bradykinin MeSH
- doxorubicin chemie MeSH
- koncentrace vodíkových iontů MeSH
- myši MeSH
- nádorové mikroprostředí MeSH
- nádory * farmakoterapie MeSH
- nanomedicína MeSH
- polymery * chemie MeSH
- zvířata MeSH
- Check Tag
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- bradykinin MeSH
- doxorubicin MeSH
- polymery * MeSH
We recently prepared pH-responsive HPMA copolymer conjugates of bradykinin (P-BK), which release BK in response to the acidic tumor microenvironment, and found that administration of P-BK increased the tumor accumulation and therapeutic efficacy of nanomedicine. Because the release of BK from P-BK determines its onset of action, P-BKs with different release rates were prepared, and their properties were evaluated. The release kinetics were significantly altered by substitution proximal to hydrazone bond, release constant of methyl-substituted P-BK (P-MeBK) was approximately 4- and 80-fold higher than that of cyclopropyl-substituted P-BK (P-CPBK) and phenyl-substituted P-BK (P-PhBK). None of the P-BKs were active, but the release of BK restored their BK-like activity. Pre-administration of the P-BKs increased the tumor accumulation of nanomedicine in C26 tumor-bearing mice by 2- and 1.4-fold for P-MeBK and P-PhBK at 3 and 6 h. Altogether, this study provides insights into the design of pH-responsive nanodrugs with the desired release properties to target acidic lesions such as cancer and inflammation.
Citace poskytuje Crossref.org